

PATENT
Customer No. 22,852
Attorney Docket No. 08702.0009-03000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
LEONARD et al.) Group Art Unit: 1645 (Previous
) Application Serial no. 09/512,930)
Filed: Herewith)
) Examiner: N.M. Minnifield ((Previous
For: USE OF IL-12 AND IL-12) Application Serial no. 09/512,930)
ANTAGONISTS IN THE)
TREATMENT OF AUTOIMMUNE)
DISEASES)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed with the initial filing of the above-referenced continuation patent application.

Copies of the listed documents are attached. Applicants respectfully request that the Examiner consider the listed references and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the

documents as prior art against any claims in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law.

Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: September 11, 2003

By: Rebecca M. McNeill
Rebecca M. McNeill
Reg. No. 43,796

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER ^{LLP}

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	08702.0009-03000	Appln. No.	TBA
Applicant	LEONARD et al.		
Filing Date	Herewith	Group:	TBA

U.S. PATENT DOCUMENTS							
Examiner Initial*		Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
		5,536,657	16 Jul. 1996	Chua <i>et al.</i>			
		5,650,492	22 Jul. 1997	Gately <i>et al.</i>			
		5,840,530	24 Nov. 1998	Gubler <i>et al.</i>			
		5,852,176	22 Dec. 1998	Gubler <i>et al.</i>			
		5,853,721	29 Dec. 1998	Gately <i>et al.</i>			
		5,955,476	21 Sep. 1999	Muller <i>et al.</i>			
		5,969,102	19 Oct. 1999	Bram <i>et al.</i>			
		6,054,487	25 Apr. 2000	Sekut <i>et al.</i>			
		6,225,117 B1	01 May 2001	Gately <i>et al.</i>			
		6,258,562 B1	10 Jul. 2001	Salfeld <i>et al.</i>			
		6,338,848 B1	15 Jan. 2002	Leonard <i>et al.</i>			
		6,469,017 B1	22 Oct. 2002	Klaus <i>et al.</i>			

FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
		WO 92/05256 ✓	02 Apr. 1992	WIPO			
		WO 93/19770 ✓	14 Oct. 1993	WIPO			
		WO 98/16248 ✓	23 Apr. 1998	WIPO			
		WO 98/22137 ✓	28 May 1998	WIPO			
		WO 98/41232 ✓	24 Sep. 1998	WIPO			
		WO 99/36073 ✓	22 Jul. 1999	WIPO			
		WO 99/37682 ✓	29 Jul. 1999	WIPO			
		0 433 827 A2 ✓	26 Jun. 1991	EPO			
		0 625 354 A1 ✓	23 Nov 1994	EPO			Yes - Abstract; See also CA 2,123,049
		0 638 644 A1 ✓	15 Feb 1995	EPO			
		0 640 689 A2 ✓	1 Mar 1995	309			

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	08702.0009-03000	Appln. No.	TBA
Applicant	LEONARD et al.		
Filing Date	Herewith	Group:	TBA

FOREIGN PATENT DOCUMENTS						
	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
	2,123,049	✓ 8 Nov 1999	Canada			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Arnaudova <i>et al.</i> , Application of Interferon- γ Containing Gel for Local Treatment of Skin Ulcers in Autoimmune Vasculitides and Skin Changes in Progressive Systemic Sclerosis, <i>The Journal of Rheumatology</i> , 20:1445-1446 (1993). ✓
	Bach, Immunosuppressive Therapy of Autoimmune Diseases, <i>Immunology Today</i> , 14:322-326 (1993). ✓
	Bach, Immunosuppressive Therapy of Autoimmune Diseases, <i>Trends in Pharmacological Sciences</i> , 14:213-216 (1993). ✓
	Balashov <i>et al.</i> , Increased Interleukin 12 Production in Progressive Multiple Sclerosis: Induction by Activated CD4 ⁺ T Cells Via CD40 Ligand, <i>Proceedings of the National Academy of Sciences U.S.A.</i> , 94:599-603 (1997). ✓
	Bankhurst, Interferons and Systemic Lupus Erythematosus, <i>Journal of Rheumatology</i> , 14:63-67 (1987). ✓
	Baron <i>et al.</i> , Production of Tumor Necrosis Factor and Other Proinflammatory Cytokines by Human Mononuclear Phagocytes Stimulated with Myelin P2 Protein, <i>Proceedings of the National Academy of Sciences U.S.A.</i> , 90:4414-4418 (1993). ✓
	Baron <i>et al.</i> , Surface Expression of α 4 Integrin by CD4 T Cells is Required for Their Entry into Brain Parenchyma, <i>Journal of Experimental Medicine</i> , 177:57-68 (1993). ✓
	Becher <i>et al.</i> , Experimental Autoimmune Encephalitis and Inflammation in the Absence of Interleukin-12, <i>Journal of Clinical Investigation</i> , 110(4):493-497 (2002). ✓
	Benson <i>et al.</i> , The role of IL-23 in experimental autoimmune encephalomyelitis, <i>FASEB Journal</i> , 16(5):A1045 (2002). ✓
	Borigini <i>et al.</i> , Combination Therapy, <i>Bailliere's Clinical Rheumatology</i> 9:689-710 (1995). ✓
	Butler <i>et al.</i> , Anti-IL-12 and Anti-TNF Antibodies Synergistically Suppress the Progression of Murine Collagen-Induced Arthritis, <i>European Journal of Immunology</i> , 29:2205-2212 (1999). ✓
	Campbell <i>et al.</i> , Essential Role for Interferon- γ and Interleukin-6 in Autoimmune Insulin-Dependent Diabetes in NOD/Wehi Mice, <i>Journal of Clinical Investigation</i> , 87:739-742 (1991). ✓
	Castaño <i>et al.</i> , Type-I Diabetes: A Chronic Autoimmune Disease of Human, Mouse, and Rat, <i>Annual Review of Immunology</i> , 8:647-679 (1990). ✓
	Chan <i>et al.</i> , Induction of Interferon γ Production by Natural Killer Cell Stimulatory Factor: Characterization of the Responder Cells and Synergy with Other Inducers, <i>Journal of Experimental Medicine</i> , 173:869-879 (1991). ✓

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	08702.0009-03000	Appln. No.	TBA
Applicant	LEONARD et al.		
Filing Date	Herewith	Group:	TBA

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Charteris <i>et al.</i> , Interferon-Gamma (IFN- γ) Production <i>In Vivo</i> in Experimental Autoimmune Uveoretinitis, <i>Immunology</i> , 75:463-467 (1992). ✓
	Chizzonite <i>et al.</i> , IL-12 Receptor I. Characterization of the Receptor on Phytohemagglutinin-Activated Human Lymphoblasts, <i>The Journal of Immunology</i> , 148:3117-3124 (1992). ✓
	Chizzonite <i>et al.</i> , IL-12: Monoclonal Antibodies Specific for the 40-kDa Subunit Block Receptor Binding and Biologic Activity on Activated Human Lymphoblasts, <i>The Journal of Immunology</i> , 147:1548-1556 (1991). ✓
	Chofflon <i>et al.</i> , Tumor Necrosis Factor α Production as a Possible Predictor of Relapse in Patients with Multiple Sclerosis, <i>European Cytokine Network</i> , 3:523-531 (1992). ✓
	Chua <i>et al.</i> , Expression Cloning of a Human IL-12 Receptor Component: A New Member of the Cytokine Receptor Superfamily with Strong Homology to gp130, <i>The Journal of Immunology</i> , 153:128-136 (1994). ✓
	Constantinescu <i>et al.</i> , IL-12 Reverses the Suppressive Effect of the CD40 Ligand Blockade on Experimental Autoimmune Encephalomyelitis (EAE), <i>Journal of the Neurological Sciences</i> , 171:60-64 (1999). ✓
	Deguchi <i>et al.</i> , Tumour Necrosis Factor/Cachectin Plays a Key Role in Autoimmune Pulmonary Inflammation in Lupus-Prone Mice, <i>Clinical and Experimental Immunology</i> , 85:392-395 (1991). ✓
	Duchmann <i>et al.</i> , Interleukin-12 mRNA is Induced in Lamina Propria Mononuclear Cells from Patients with Inflammatory Bowel Disease (IBD), <i>Gastroenterology (Suppl.)</i> , 104:A693 (1993). ✓
	Feldmann <i>et al.</i> , Evaluation of the Role of Cytokines in Autoimmune Disease: The Importance of TNF α in Rheumatoid Arthritis, <i>Progress in Growth Factor Research</i> , 4:247-255 (1992). ✓
	Fox <i>et al.</i> , Anti-Interleukin-12 Antibody: Potential Role in Preventing Relapses of Multiple Sclerosis, <i>BioDrugs</i> , 13:233-241 (2000). ✓
	Fujihira <i>et al.</i> , Suppression and Acceleration of Autoimmune Diabetes by Neutralization of Endogenous Interleukin-12 in NOD Mice, <i>Diabetes</i> , 49:1998-2006 (2000). ✓
	Funauchi <i>et al.</i> , Serum Level of Interferon- γ in Autoimmune Diseases, <i>Tohoku Journal of Experimental Medicine</i> , 164:259-267 (1991). ✓
	Fuss <i>et al.</i> , Disparate CD4 ⁺ Lamina Propria (LP) Lymphokine Secretion Profiles in Inflammatory Bowel Disease, <i>The Journal of Immunology</i> , 157(3):1261-1270 (1996). ✓
	Gately <i>et al.</i> , Interleukin-12 Antagonist Activity of Mouse Interleukin-12 p40 Homodimer <i>in Vitro</i> and <i>in Vivo</i> , <i>Annals New York Academy of Sciences</i> , 795:1-12 (1996). ✓
	Germann <i>et al.</i> , IL-12, a Cytokine with Multiple Effects on T _H 1-, but not on T _H 2-cells, <i>Immunobiology</i> , 186:38 (1992). ✓
	Germann <i>et al.</i> , Administration of interleukin 12 in combination with type II collagen induces severe arthritis in DBA/1 mice, <i>Proceedings of the National Academy of Sciences U.S.A.</i> , 92:4823-4827 (1995). ✓

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	08702.0009-03000	Appln. No.	TBA
Applicant	LEONARD et al.		
Filing Date	Herewith	Group:	TBA

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Godfrey <i>et al.</i> , A Developmental Pathway Involving Four Phenotypically and Functionally Distinct Subsets of CD3 ⁺ CD4 ⁺ CD8 ⁺ Triple-Negative Adult Mouse Thymocytes Defined by CD44 and CD25 Expression, <i>The Journal of Immunology</i> , 150:4244-4252 (1993). ✓
	Gran <i>et al.</i> , IL-12p35-Deficient Mice are Susceptible to Experimental Autoimmune Encephalomyelitis: Evidence for Redundancy in the IL-12 System in the Induction of Central Nervous System Autoimmune Demyelination, <i>The Journal of Immunology</i> , 169(12):7104-7110 (2002). ✓
	Greig <i>et al.</i> , A Comparison of the Effects of Melengestrol Acetate and Hydrocortisone Acetate on Experimental Allergic Encephalomyelitis in Rats, <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 173:85-93 (1970). ✓
	Gubler <i>et al.</i> , Coexpression of Two Distinct Genes is Required to Generate Secreted Bioactive Cytotoxic Lymphocyte Maturation Factor, <i>Proceedings of the National Academy of Sciences U.S.A.</i> , 88:4143-4147 (1991). ✓
	Harris <i>et al.</i> , Therapeutic Antibodies - The Coming of Age, <i>Trends in Biotechnology</i> , 11:42-44 (1993). ✓
	Heremans <i>et al.</i> , Role of Endogenous Interleukin-12 (IL-12) in Induced and Spontaneous Relapses of Experimental Autoimmune Encephalomyelitis in Mice, <i>European Cytokine Network</i> , 10:171-179 (1999). ✓
	Hess <i>et al.</i> , High Doses of Interleukin-12 Inhibit the Development of Joint Disease in DBA/1 Mice Immunized with Type II Collagen in Complete Freund's Adjuvant, <i>European Journal of Immunology</i> , 26:187-191 (1996). ✓
	Higgins <i>et al.</i> , Suppression of Experimental Autoimmune Encephalomyelitis by Oral Administration of Myelin Basic Protein and Its Fragments, <i>The Journal of Immunology</i> , 140:440-445 (1988). ✓
	Hofman <i>et al.</i> , Immunoregulatory Molecules and IL 2 Receptors Identified in Multiple Sclerosis Brain, <i>The Journal of Immunology</i> , 136:3239-3245 (1986). ✓
	Hofman <i>et al.</i> , Lymphokines and Immunoregulatory Molecules in Subacute Sclerosing Panencephalitis, <i>Clinical Immunology and Immunopathology</i> , 58:331-342 (1991). ✓
	Hofman <i>et al.</i> , Tumor Necrosis Factor Identified in Multiple Sclerosis Brain, <i>Journal of Experimental Medicine</i> , 170:607-612 (1989). ✓
	Hunter <i>et al.</i> , Immunoregulation by Interleukin-12 in MB49.1 Tumor-Bearing Mice: Cellular and Cytokine-Mediated Effector Mechanisms, <i>European Journal of Immunology</i> , 27:3438-3446 (1997). ✓
	Ichikawa <i>et al.</i> , Anti-IL-12 Antibody Prevents the Development and Progression of Multiple Sclerosis-Like Relapsing-Remitting Demyelinating Disease in NOD Mice Induced with Myelin Oligodendrocyte Glycoprotein Peptide, <i>Journal of Neuroimmunology</i> , 102:56-66 (2000). ✓
	Jaffe, Combination Therapy of Rheumatoid Arthritis—Rationale and Overview, <i>Journal of Rheumatology</i> , 17 (supplement 25): 24-27 (1990). ✓
	Joosten <i>et al.</i> , Blockade of Endogenous Interleukin 12 Results in Suppression of Murine Streptococcal Cell Wall Arthritis by Enhancement of Interleukin 10 and Interleukin 1Ra, <i>Annals of Rheumatic Diseases</i> , 59(3): 196-205 (2000). ✓

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	08702.0009-03000	Appln. No.	TBA
Applicant	LEONARD et al.		
Filing Date	Herewith	Group:	TBA

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Karlsson <i>et al.</i> , Autoimmune Endocrinopathies 5: Autoimmune Disease of the Adrenal Cortex, Pituitary, Parathyroid Glands and Gastric Mucosa, <i>Journal of Internal Medicine</i> , 234:379-386 (1993). ✓
	Kim <i>et al.</i> , The role of IL-12 in Inflammatory Activity of Patients with Rheumatoid Arthritis (RA), <i>Clinical and Experimental Immunology</i> , 119:175-181 (2000). ✓
	Kobayashi <i>et al.</i> , Identification and Purification of Natural Killer Cell Stimulatory Factor (NKSF), a Cytokine with Multiple Biologic Effects on Human Lymphocytes, <i>Journal of Experimental Medicine</i> , 170:827-845 (1989). ✓
	Lagoo <i>et al.</i> , Proinflammatory Cytokine Production by Rheumatoid Arthritis Synovial Fibroblasts, <i>Journal of Cellular Biochemistry (Suppl. O)</i> , 17:146, EZ410 (1993). ✓
	Leonard <i>et al.</i> , Effects of Single-Dose Interleukin-12 Exposure on Interleukin-12-Associated Toxicity and Interferon- γ Production, <i>Blood</i> , 90:2541-2548 (1997). ✓
	Leonard <i>et al.</i> , Prevention of Experimental Autoimmune Encephalomyelitis by Antibodies Against Interleukin 12, <i>Journal of Experimental Medicine</i> , 181:381-386 (1995). ✓
	Leonard <i>et al.</i> , Regulation of Experimental Autoimmune Encephalomyelitis by Interleukin-12, <i>Annals New York Academy of Sciences</i> , 795:216-226 (1996). ✓
	Leonard <i>et al.</i> , Regulation of the Inflammatory Response in Animal Models of Multiple Sclerosis by Interleukin-12, <i>Critical Reviews in Immunology</i> , 17:545-553 (1997). ✓
	Lernmark <i>et al.</i> , Autoimmune Endocrinopathies 3: Islet Cell Autoimmunity, <i>Journal of Internal Medicine</i> , 234:361-369 (1993). ✓
	Maini, Croonian Lecture 1995, The role of Cytokines in Rheumatoid Arthritis, <i>Journal of Royal College of Physicians of London</i> , 30:344-351 (1996). ✓
	Malfait <i>et al.</i> , Blockade of IL-12 During the Induction of Collagen-Induced Arthritis (CIA) Markedly Attenuates the Severity of the Arthritis, <i>Clinical and Experimental Immunology</i> , 111:377-383 (1998). ✓
	Manetti <i>et al.</i> , Natural Killer Cell Stimulatory Factor (Interleukin 12 [IL-12]) Induces T Helper Type 1 (Th1)-Specific Immune Responses and Inhibits the Development of IL-4-Producing Th Cells, <i>Journal of Experimental Medicine</i> , 177:1199-1204 (1993). ✓
	Matthys, et al., Anti-IL-12 Antibody Prevents the Development and Progression of Collagen-Induced Arthritis in IFN- γ Receptor-Deficient Mice, <i>European Journal of Immunology</i> , 28 (7): 2143-2151 (1998). ✓
	Mattner <i>et al.</i> , The interleukin-12 subunit p40 specifically inhibits effects of the interleukin-12 heterodimer, <i>European Journal of Immunology</i> , 23:2202-2208 (1993). ✓
	McIntyre <i>et al.</i> , Reduced Incidence and Severity of Collagen-Induced Arthritis in Interleukin-12-Deficient Mice, <i>European Journal of Immunology</i> 26(12): 2933-2938 (1996). ✓
	Merrill <i>et al.</i> , Inflammatory Leukocytes and Cytokines in the Peptide-Induced Disease of Experimental Allergic Encephalomyelitis in SJL and B10.PL Mice, <i>Proceedings of the National Academy of Sciences U.S.A.</i> , 89:574-578 (1992). ✓

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	08702.0009-03000	Appln. No.	TBA
Applicant	LEONARD et al.		
Filing Date	Herewith	Group:	TBA

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Merrill <i>et al.</i> , T Cell Lines Established from Multiple Sclerosis Cerebrospinal Fluid T cells Using Human Retroviruses, <i>Journal of Neuroimmunology</i> , 21:213-226 (1989). ✓
	Moller <i>et al.</i> , Inhibition of IL-12 Production by Thalidomide, <i>Journal of Immunology</i> , 159 (10): 5157-5161 (1997). ✓
	Neurath <i>et al.</i> , Antibodies to Interleukin 12 Abrogate Established Experimental Colitis in Mice, <i>J. Exp. Medicine</i> , 182:1281-1290 (1995). ✓
	Ozmen <i>et al.</i> , Interleukin 12, Interferon γ , and Tumor Necrosis Factor α Are the Key Cytokines of the Generalized Shwartzman Reaction, <i>J. Exp. Med.</i> , 180:907-915 (1994). ✓
	Panitch <i>et al.</i> , Treatment of Multiple Sclerosis with Gamma Interferon: Exacerbations Associated with Activation of the Immune System, <i>Neurology</i> , 37:1097-1102 (1987). ✓
	Peeva <i>et al.</i> , Rheumatoid Arthritis Exacerbation Caused by Exogenous Interleukin-12, <i>Arthritis & Rheumatism</i> , 43:461-463 (2000). ✓
	Romagnani, S., Human TH1 and TH2 subsets: regulation of differentiation and role in protection and immunopathology, <i>Int. Arch. Allergy Immunol.</i> 98:279-285 (1992). ✓
	Rothe <i>et al.</i> , Suppression of Cyclophosphamide Induced Diabetes Development and Pancreatic Th1 Reactivity in NOD Mice Treated with the Interleukin (IL)-12 Antagonist IL-12(p40) ₂ , <i>Diabetologia</i> , 40:641-646 (1997). ✓
	Saito <i>et al.</i> , Effect of CD80 and CD86 Blockade and Anti-Interleukin-12 Treatment on Mouse Acute Graft-Versus-Host Disease, <i>European Journal of Immunology</i> , 26:3098-3106 (1996). ✓
	Serreze, Autoimmune Diabetes Results from Genetic Defects Manifest by Antigen Presenting Cells, <i>FASEB Journal</i> , 7:1092-1096 (1993). ✓
	Simon <i>et al.</i> , Divergent T-cell Cytokine Patterns in Inflammatory Arthritis, <i>Proceedings of the National Academy of Sciences U.S.A.</i> , 91:8562-8566 (1994). ✓
	Smith <i>et al.</i> , Interleukin-12 Induces Relapse in Experimental Allergic Encephalomyelitis in the Lewis Rat, <i>American Journal of Pathology</i> , 150:1909-1917 (1997). ✓
	Smith <i>et al.</i> , The Role of T Cells in Myosin-Induced Autoimmune Myocarditis, <i>Clinical Immunology and Immunopathology</i> , 68:100-106 (1993). ✓
	Steinman, Autoimmune Disease: Misguided Assaults on the Self Produce Multiple Sclerosis, Juvenile Diabetes and Other Chronic Illnesses: Promising Therapies are Emerging, <i>Scientific American</i> , 107-114 (September 1993). ✓
	Tang <i>et al.</i> , The Effects of a Monoclonal Antibody to Interferon- γ on Experimental Autoimmune Thyroiditis (EAT): Prevention of Disease and Decrease of EAT-Specific T Cells, <i>European Journal of Immunology</i> , 23:275-278 (1993). ✓
	Trembleau <i>et al.</i> , The role of IL-12 in the induction of organ-specific autoimmune diseases, <i>Immunology Today</i> , 16:383-386 (1995). ✓
	Trembleau <i>et al.</i> , Interleukin 12 Administration Induces T Helper Type 1 Cells and Accelerates Autoimmune Diabetes in NOD Mice, <i>J. Exp. Med.</i> , 181:817-821 (1995). ✓

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	08702.0009-03000	Appln. No.	TBA
Applicant	LEONARD et al.		
Filing Date	Herewith	Group:	TBA

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Triantaphyllopoulos <i>et al.</i> , Amelioration of Collagen-Induced Arthritis and Suppression of Interferon- γ , Interleukin-12, and Tumor Necrosis Factor α Production by Interferon- β Gene Therapy, <i>Arthritis Rheum</i> , 42 (1): 90-99 (1999). ✓
	Trinchieri <i>et al.</i> , Natural Killer Cell Stimulatory Factor (NKSF) or Interleukin-12 is a Key Regulator of Immune Response and Inflammation, <i>Progress in Growth Factor Research</i> , 4:355-368 (1992). ✓
	Van der Veen <i>et al.</i> , The Effect of Methylprednisolone Pulse Therapy on Methotrexate Treatment of Rheumatoid Arthritis, <i>Clinical Rheumatology</i> , 12:500-505 (1993). ✓
	Verhoeven <i>et al.</i> , Combination Therapy in Rheumatoid Arthritis: Updated Systematic Review, <i>British Society for Rheumatology</i> , 37:612-619 (1998). ✓
	Veys <i>et al.</i> , Interferon Gamma in Rheumatoid Arthritis - A Double Blind Study Comparing Human Recombinant Interferon Gamma with Placebo, <i>The Journal of Rheumatology</i> , 15:570-574 (1988). ✓
	Via <i>et al.</i> , IL12 Prevents Autoimmunity in a Murine Model of SLE, <i>Arthritis and Rheumatism</i> , 36:148 (1993). ✓
	Via <i>et al.</i> , IL-12 Stimulates the Development of Acute Graft-Versus-Host Disease in Mice that Normally Would Develop Chronic, Autoimmune Graft-Versus-Host Disease, <i>The Journal of Immunology</i> , 153(9):4040-4047 (1994). ✓
	Vitali <i>et al.</i> , Immunotherapy in Rheumatoid Arthritis, <i>The International Journal of Artificial Organs</i> , 16:196-200 (1993). ✓
	Waldburger <i>et al.</i> , Adoptive Transfer of Experimental Allergic Encephalomyelitis After <i>in Vitro</i> Treatment with Recombinant Murine Interleukin-12, <i>American Journal of Pathology</i> , 148:375-382 (1996). ✓
	Wilske, Approaches to the Management of Rheumatoid Arthritis: Rationale for Early Combination Therapy, <i>British Journal of Rheumatology</i> , 32 (supplement 1) 24-27 (1993). ✓
	Wysocka <i>et al.</i> , Interleukin-12 is required for interferon- γ production and lethality in lipopolysaccharide-induced shock in mice, <i>European Journal of Immunology</i> , 25:672-676 (1995). ✓
Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce

393900_1.DOC